WO2002054065A3 - Reversible mhc multimer staining for functional purification of antigen-specific t cells - Google Patents

Reversible mhc multimer staining for functional purification of antigen-specific t cells Download PDF

Info

Publication number
WO2002054065A3
WO2002054065A3 PCT/EP2001/015353 EP0115353W WO02054065A3 WO 2002054065 A3 WO2002054065 A3 WO 2002054065A3 EP 0115353 W EP0115353 W EP 0115353W WO 02054065 A3 WO02054065 A3 WO 02054065A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
antigen
specific
mhc multimer
multimer staining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/015353
Other languages
French (fr)
Other versions
WO2002054065A2 (en
Inventor
Dirk H Busch
Hermann Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IBA Lifesciences GmbH
Original Assignee
IBA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IBA GmbH filed Critical IBA GmbH
Priority to CA2467434A priority Critical patent/CA2467434C/en
Priority to US10/451,865 priority patent/US7776562B2/en
Priority to JP2002554713A priority patent/JP4416400B2/en
Priority to EP01986941.1A priority patent/EP1346217B1/en
Publication of WO2002054065A2 publication Critical patent/WO2002054065A2/en
Publication of WO2002054065A3 publication Critical patent/WO2002054065A3/en
Anticipated expiration legal-status Critical
Priority to US12/843,763 priority patent/US8298782B2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ecology (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a new method for reversible staining and functional isolation or characterization of cells, e.g. antigen-specific T cells. With this technique, the original functional status of cells can be substantially maintained after their identification and purification. Thus, this new method is of broad benefit for basic research and clinical applications.
PCT/EP2001/015353 2000-12-28 2001-12-28 Reversible mhc multimer staining for functional purification of antigen-specific t cells Ceased WO2002054065A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2467434A CA2467434C (en) 2000-12-28 2001-12-28 Reversible mhc multimer staining for functional purification of antigen-specific t cells
US10/451,865 US7776562B2 (en) 2000-12-28 2001-12-28 Reversible MHC multimer staining for functional purification of antigen-specific T cells
JP2002554713A JP4416400B2 (en) 2000-12-28 2001-12-28 Reversible MHC multimer staining method for functional purification of antigen-specific T-cells
EP01986941.1A EP1346217B1 (en) 2000-12-28 2001-12-28 Reversible mhc multimer staining for functional purification of antigen-specific t cells
US12/843,763 US8298782B2 (en) 2000-12-28 2010-07-26 Reversible MHC multimer staining for functional purification of antigen-specific T cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00128634.3 2000-12-28
EP00128634A EP1227321A1 (en) 2000-12-28 2000-12-28 Reversible MHC multimer staining for functional purification of antigen-specific T cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10451865 A-371-Of-International 2001-12-28
US12/843,763 Continuation US8298782B2 (en) 2000-12-28 2010-07-26 Reversible MHC multimer staining for functional purification of antigen-specific T cells

Publications (2)

Publication Number Publication Date
WO2002054065A2 WO2002054065A2 (en) 2002-07-11
WO2002054065A3 true WO2002054065A3 (en) 2002-11-28

Family

ID=8170850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/015353 Ceased WO2002054065A2 (en) 2000-12-28 2001-12-28 Reversible mhc multimer staining for functional purification of antigen-specific t cells

Country Status (5)

Country Link
US (2) US7776562B2 (en)
EP (2) EP1227321A1 (en)
JP (1) JP4416400B2 (en)
CA (1) CA2467434C (en)
WO (1) WO2002054065A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
EP1982176A1 (en) * 2006-01-30 2008-10-22 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
EP1878744A1 (en) * 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
AU2007353319A1 (en) 2006-11-15 2008-11-20 Invitrogen Dynal As Methods for reversibly binding a biotin compound to a support
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3620465B1 (en) * 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (en) 2008-02-28 2019-09-09 Dako Denmark As MHC multimers for Borrelia diagnostics and disease
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
WO2011034115A1 (en) * 2009-09-17 2011-03-24 Jsr株式会社 Dissociation method and dissociation agent for avidin and biotin
EP4219759A3 (en) 2010-05-06 2023-09-06 Adaptive Biotechnologies Corporation Monitoring health and disease status using clonotype profiles
CN103124740B (en) * 2010-09-21 2015-09-02 美国卫生和人力服务部 Anti-SSX-2T cell receptor and associated materials and using method
WO2012044999A2 (en) 2010-10-01 2012-04-05 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
TR201811128T4 (en) 2011-07-18 2018-08-27 Iba Gmbh Reversible staining of a target cell.
WO2013056090A1 (en) * 2011-10-12 2013-04-18 University Of Connecticut Affinity-based materials for the non-destructive separation and recovery of cells
RU2746407C1 (en) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Chromatographic isolation of cells and other complex biological materials
CN102662054B (en) * 2012-05-10 2014-08-13 东南大学 Method for synchronously detecting quantity and functions of specific thymus dependent lymph cells
WO2014076277A1 (en) 2012-11-16 2014-05-22 Iba Gmbh Streptavidin muteins and methods of using them
CN113354744A (en) 2013-12-20 2021-09-07 弗雷德哈钦森癌症研究中心 Tagged chimeric effector molecules and receptors thereof
WO2015109389A1 (en) 2014-01-21 2015-07-30 Stemcell Technologies Inc. Method for separating target entities from a sample using a composition of mono-specific tetrameric antibody complexes coupled to a surface
BR112016024072B1 (en) 2014-04-16 2021-02-09 Juno Therapeutics Gmbh in vitro method of stimulating a cell population
RU2763795C2 (en) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Methods of isolating, culturing and genetic engineering cell populations of the immune system for adoptive therapy
CA2945414C (en) 2014-04-30 2023-05-09 Iba Gmbh Method of isolating a target cell
EP3037820A1 (en) 2014-12-27 2016-06-29 Miltenyi Biotec GmbH Cell detection methods and reagents having a releasable labelling moiety
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
JP6657721B2 (en) 2015-09-30 2020-03-04 ソニー株式会社 Cell analysis method, cell analysis chip, cell analysis reagent, cell analysis kit, and cell analysis device
SG11201803330WA (en) * 2015-10-22 2018-05-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
US11248238B2 (en) 2015-10-22 2022-02-15 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
JP7194020B2 (en) 2015-10-22 2022-12-21 ジュノ セラピューティクス ゲーエムベーハー Cell culture method and kit and device therefor
EP3443123B1 (en) 2016-04-11 2021-08-11 Board of Regents, The University of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
CN109983133B (en) * 2016-06-28 2023-09-08 慕尼黑工业大学 Combination of reversible and irreversible cell labels for analysis of receptor-ligand Koff rates
TWI795365B (en) 2016-08-11 2023-03-11 荷蘭商凱特製藥歐洲公司 Methods of making and using soluble mhc molecules
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
EP3336545A1 (en) 2016-12-13 2018-06-20 Miltenyi Biotec GmbH Reversible labeling of antigens in biological specimens
EP3336546B1 (en) 2016-12-13 2020-07-01 Miltenyi Biotec B.V. & Co. KG Reversible cell labelling with conjugates having two releasable binding sites
MX2019008538A (en) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods.
JP7339160B2 (en) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー Oligomeric particle reagents and methods of use thereof
BR112020001719A2 (en) 2017-07-29 2020-07-21 Juno Therapeutics Inc reagents for cell expansion that express recombinant receptors
EP3489684B1 (en) 2017-11-27 2024-06-26 Miltenyi Biotec B.V. & Co. KG Method for photobleaching stained cells
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
CN116148467A (en) * 2017-12-12 2023-05-23 清华大学 Kit of reagents for detecting interactions between post-translationally modified proteins and their ligands
CN113474450A (en) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 Methods of producing engineered cells and compositions of said engineered cells
WO2020048876A1 (en) 2018-09-03 2020-03-12 Technische Universitaet Muenchen A double peptide tag combining reversibility and flexible functionalization
MX2021002574A (en) 2018-09-11 2021-06-08 Juno Therapeutics Inc METHODS FOR THE ANALYSIS BY MASS SPECTROMETRY OF COMPOSITIONS OF MODIFIED CELLS.
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
EP3877054B1 (en) 2018-11-06 2023-11-01 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
EP3953346A1 (en) 2019-04-09 2022-02-16 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
WO2020207963A1 (en) 2019-04-12 2020-10-15 Miltenyi Biotec B.V. & Co. KG Conjugates having an enzymatically releasable detection moiety and a barcode moiety
EP3969447A1 (en) 2019-05-17 2022-03-23 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
CA3142108A1 (en) 2019-05-28 2020-12-03 Miltenyi Biotec B.V. & Co. KG Method for generation of genetically modified t cells
MX2021015125A (en) 2019-06-07 2022-04-06 Juno Therapeutics Inc AUTOMATED CULTURE OF T CELLS.
MX2021015675A (en) 2019-06-26 2022-02-03 Nurix Therapeutics Inc SUBSTITUTED BENCYL-TRIAZOLE COMPOUNDS FOR THE INHIBITION OF CBL-B AND OTHER USES THEREOF.
WO2021021761A1 (en) 2019-07-30 2021-02-04 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
EP4022637A2 (en) 2019-08-30 2022-07-06 Juno Therapeutics, Inc. Machine learning methods for classifying cells
US20220315894A1 (en) 2019-09-11 2022-10-06 Miltenyi Biotec B.V. & Co. KG Method for Transduction of T Cells in the Presence of Malignant Cells
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
WO2021122185A1 (en) 2019-12-20 2021-06-24 Miltenyi Biotec B.V. & Co. KG Reversible cell detection via mhc with conjugates having an enzymatically cleavable detection moiety
US20230090117A1 (en) 2020-01-28 2023-03-23 Juno Therapeutics, Inc. Methods for t cell transduction
WO2021152178A1 (en) 2020-01-31 2021-08-05 Cell.Copedia GmbH Methods of isolating a biological entity
IL295381B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
IL295384B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
WO2021231661A2 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
EP3916393B1 (en) 2020-05-27 2023-01-25 Miltenyi Biotec B.V. & Co. KG Method for detection of cells by repetitive staining and destaining
EP4204809A1 (en) 2020-08-27 2023-07-05 Miltenyi Biotec B.V. & Co. KG Releasable reagents for cell separation
EP4211471A1 (en) 2020-09-07 2023-07-19 Miltenyi Biotec B.V. & Co. KG Conjugates having an enzymatically releasable detection moiety and a barcode moiety
US20250283037A1 (en) 2021-05-06 2025-09-11 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
WO2023017115A1 (en) 2021-08-11 2023-02-16 Iba Lifesciences Gmbh Fractionation of cells based on a marker protein
EP4227423A1 (en) 2022-02-09 2023-08-16 Technische Universität München Means and methods for identifying high affinity t-cells
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
CN121100267A (en) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 Machine learning method for predicting cell phenotype using holographic imaging
CN121002052A (en) 2023-02-03 2025-11-21 C3S2 有限公司 Methods for engineered immune cells used in non-viral production
KR20260005874A (en) 2023-02-28 2026-01-12 주노 쎄러퓨티크스 인코퍼레이티드 Cell therapy for treating systemic autoimmune diseases
EP4484441A1 (en) 2023-06-26 2025-01-01 Eberhard-Karls-Universität Tübingen Mhc-class i derived polypeptide
AU2024364039A1 (en) 2023-10-18 2026-04-16 Tq Therapeutics Gmbh A method of manufacturing a cellular therapy product and respective kits and devices

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005287A1 (en) * 1994-08-09 1996-02-22 Anergen, Inc. A method for the isolation of t cells from peripheral blood
WO1997011183A1 (en) * 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
EP0835934A2 (en) * 1996-10-10 1998-04-15 Institut für Bioanalytik GmbH Muteins of streptavidin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948590A (en) * 1987-06-09 1990-08-14 Yale University Avidin or streptavidin conjugated liposomes
DE4237113B4 (en) * 1992-11-03 2006-10-12 "Iba Gmbh" Peptides and their fusion proteins, expression vector and method of producing a fusion protein
AU716154B2 (en) * 1995-09-01 2000-02-17 University Of Washington Interactive molecular conjugates
US5985658A (en) * 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
FR2841905B1 (en) * 2002-07-05 2004-09-03 Centre Nat Rech Scient FAB MUTANTS OF CHIMERE 13B8.2 ANTI-CD4 ANTIBODIES AND THEIR APPLICATIONS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005287A1 (en) * 1994-08-09 1996-02-22 Anergen, Inc. A method for the isolation of t cells from peripheral blood
WO1997011183A1 (en) * 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
EP0835934A2 (en) * 1996-10-10 1998-04-15 Institut für Bioanalytik GmbH Muteins of streptavidin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
VOSS SELMA ET AL: "Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification.", PROTEIN ENGINEERING, vol. 10, no. 8, August 1997 (1997-08-01), pages 975 - 982, XP002107709, ISSN: 0269-2139 *
YEE C ET AL: "isolation of high avidity melanoma reactive CTL from heterogeneous populations using peptide-MHC tetramers", JOURNAL OF IMMUNOLOGY, 15 February 1999 (1999-02-15), XP002156019 *
YOUDE SARAH J ET AL: "Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.", CANCER RESEARCH, vol. 60, no. 2, 15 January 2000 (2000-01-15), pages 365 - 371, XP002167445, ISSN: 0008-5472 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells

Also Published As

Publication number Publication date
JP4416400B2 (en) 2010-02-17
US8298782B2 (en) 2012-10-30
WO2002054065A2 (en) 2002-07-11
EP1346217A2 (en) 2003-09-24
CA2467434C (en) 2013-02-19
EP1227321A1 (en) 2002-07-31
US20110070605A1 (en) 2011-03-24
JP2004525354A (en) 2004-08-19
US20040082012A1 (en) 2004-04-29
US7776562B2 (en) 2010-08-17
EP1346217B1 (en) 2020-10-21
CA2467434A1 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
WO2002054065A3 (en) Reversible mhc multimer staining for functional purification of antigen-specific t cells
AU2002303343A1 (en) Methods and reagents for cell transplantation
AU2003226608A1 (en) Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
AU4487900A (en) Microelectromechanical devices useful for manipulating cells or embryos, kits thereof, methods of making same, and methods of use thereof
AU2002239826A1 (en) Methods and reagents for the isolation of nucleic acids
AU2002325758A1 (en) Cultured stromal cells and uses thereof
AU2001237995A1 (en) Assay methods for hydratable cementitious compositions
AU2002321292A1 (en) Hybrid membrane, method for the production thereof and use of said membrane
AU2002363259A1 (en) Method for the detection of cytosine methylation in immobilised DNA samples
WO2004009758A3 (en) Embryonic stem cell markers and uses thereof
AU2002353443A1 (en) Kits and methods for preparing cell samples optimized for dual staining
AU2001266127A1 (en) Method for obtaining characterised muscle-derived cell populations and uses
AU2002216968A1 (en) Plasma fraction containing bikunin, method for the production thereof and use of the same
AU2001278813A1 (en) Multiplex pcr method and kit and oligonucleotides for detection and identification of mycobacteria using the multiplex pcr method
AU2002215333A1 (en) Compositions for release of radiosensitizers, and methods of making and using the same
AU3107699A (en) Novel forms of t cell costimulatory proteins, nucleic acid molecules, and uses thereof
WO2001064837A8 (en) β NETRIN AND USES THEREOF
AU2001279067A1 (en) Cold isopressing method and mold
AU2003287227A1 (en) High temperature incubation system and method for small volumes
AU4771600A (en) Cells, culture methods and their uses
AU2001236624A1 (en) Rapid, parallel identification of cell lines
AU2002224357A1 (en) Mammalian wnt polypeptide-5
AU2002221754A1 (en) Method for anodic bonding at low temperatures
AU2001253485A1 (en) Nucleic acid sequences associated with baldness
AU2001286722A1 (en) Methods for reducing complexity of nucleic acid samples

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001986941

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002554713

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001986941

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10451865

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2467434

Country of ref document: CA